Alkermes logo

ALKS - Alkermes Share Price

$18.71 0.2  1.0%

Last Trade - 5:25pm

Sector
Healthcare
Size
Mid Cap
Market Cap £2.24bn
Enterprise Value £2.00bn
Revenue £823.2m
Position in Universe 1594th / 6416
Bullish
Bearish
Unlock ALKS Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ALKS Revenue Unlock ALKS Revenue

Net Income

ALKS Net Income Unlock ALKS Revenue

Normalised EPS

ALKS Normalised EPS Unlock ALKS Revenue

PE Ratio Range

ALKS PE Ratio Range Unlock ALKS Revenue

Dividend Yield Range

ALKS Dividend Yield Range Unlock ALKS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ALKS EPS Forecasts Unlock ALKS Revenue
Profile Summary

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated May 4, 2011
Public Since July 16, 1991
No. of Shareholders: 119
No. of Employees: 2,300
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 157,522,247
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ALKS Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ALKS
Upcoming Events for ALKS
Wednesday 12th February, 2020 Estimate
Q4 2019 Alkermes Plc Earnings Release
Thursday 23rd April, 2020 Estimate
Q1 2020 Alkermes Plc Earnings Release
Thursday 21st May, 2020 Estimate
Alkermes Plc Annual Shareholders Meeting
Similar to ALKS
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.